Given that neoantigen‐specific CD4+ T cells48, 49, 50 and Tregs51, 52, 53 play distinct roles in tumor immunity, the differential recruitment ability of IMECs towards these two CD4+ T cell subsets may impact the delicate balance between antitumor immunity and immunosuppression. The gene discussed is CD4; the disease is neoplasm.